Work requirements in Medicaid have resurfaced as part of a broader legislative package of potential changes to Medicaid designed to significantly reduce federal Medicaid spending. This brief highlights five key facts about Medicaid work requirements, including the share of Medicaid enrollees who currently work, what research shows about the impact of work requirements, and the…
Running a behavioral health practice requires balancing patient volume and case diversity, while maintaining operations. Transparent practice policies are necessary for success and ensuring high-quality, consistent patient care. The post 4 Practice Policies that Help Maintain Behavioral Health Practice Success appeared first on MedCity News.
Novo Nordisk’s Wegovy achieved statistically significant improvement in a Phase 3 study in the fatty liver disease MASH. Based on these preliminary results, the company plans to seek U.S. and European Union approvals in this indication in 2025. The post Novo Nordisk GLP-1 Drug Meets Goals of MASH Trial, Setting Stage for FDA & EMA…
To inform future directions for PEPFAR and other U.S. global health programs, this policy brief reviews the graduation policies of several institutions to identify options for consideration.
CagriSema, a dual-acting drug in development by Novo Nordisk, met the goal of a Phase 3 test in patients with obesity and type 2 diabetes. But the topline results don’t show an advantage over Eli Lilly’s commercialized obesity medication, Zepbound. The post Novo Nordisk’s Next-Gen Obesity Drug Disappoints Again With Lower Than Expected Weight Loss…
Maureen Gremminger, EVS Resident Regional Manager, Inspira Health Network in Mullica Hill, New Jersey I was an office manager at a moving company before joining Crothall’s Manager in Training program in 2012. At that time, I met Joce-Lyn Hanton, who was an operations manager. She was so inspirational; she knew everything about cleaning. The first…
Other ideas that emerged from fall 2023 summit meeting were a task force on primary care and health equity and a state scorecard on primary care
Editas Medicine says its in vivo gene-editing therapy for hemoglobinopathies has best-in-class potential, but the company plans to out-license or partner that program. Editas is shifting focusing to in vivo gene-editing therapies. The post Editas Medicine Seeks Partner for Ex Vivo Gene-Editing Program as Focus Turns to In Vivo R&D appeared first on MedCity News.
Automated solution extracts quantitative measures from existing imaging studies to improve diagnostic accuracy, reduce physician burden
Like any other tool, understanding the right problem to apply it to is the difference between success and failure. Addressing a problem is never just about technology; it’s always about people, processes, and technology. The post The AI Advantage: Reimagining the Future of Drug Development appeared first on MedCity News.